{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:48:30Z","timestamp":1772264910568,"version":"3.50.1"},"reference-count":57,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/roat5658","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:33:48Z","timestamp":1738899228000},"page":"286-298","source":"Crossref","is-referenced-by-count":2,"title":["TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma"],"prefix":"10.62347","volume":"15","author":[{"given":"Anna D","family":"Louie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M and Maitra A. Pancreatic cancer: advances and challenges. Cell 2023; 186: 1729-1754.","journal-title":"Cell"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"ZI","year":"2024","unstructured":"Hu ZI and O&#x2019;Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 2024; 21: 7-24.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hern&#xE1;ndez-Blanquisett A, Quintero-Carre&#xF1;o V, Mart&#xED;nez-&#xC1;vila MC, Porto M, Manzur-Barbur MC and Buend&#xED;a E. Metastatic pancreatic cancer: where are we? Oncol Rev 2024; 17: 11364.","DOI":"10.3389\/or.2023.11364"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: a review of current treatment and novel therapies","volume":"36","author":"Kolbeinsson","year":"2023","unstructured":"Kolbeinsson HM, Chandana S, Wright GP and Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg 2023; 36: 2129884.","journal-title":"J Invest Surg"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","unstructured":"Park W, Chawla A and O&#x2019;Reilly EM. Pancreatic cancer: a review. JAMA 2021; 326: 851-862.","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Gr&#xFC;tzmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G and Tempero MA; Australian Pancreatic Cancer Genome Initiative; Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV and Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/cancers16010056","article-title":"Understanding the genetic landscape of pancreatic ductal adenocarcinoma to support personalized medicine: a systematic review","volume":"16","author":"Pantaleo","year":"2023","unstructured":"Pantaleo A, Forte G, Fasano C, Lepore Signorile M, Sanese P, De Marco K, Di Nicola E, Latrofa M, Grossi V, Disciglio V and Simone C. Understanding the genetic landscape of pancreatic ductal adenocarcinoma to support personalized medicine: a systematic review. Cancers (Basel) 2023; 16: 56.","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Ben-Aharon I, Elkabets M, Pelossof R, Yu KH, Iacubuzio-Donahue CA, Leach SD, Lowery MA, Goodman KA and O&#x2019;Reilly EM. Genomic landscape of pancreatic adenocarcinoma in younger versus older patients: does age matter? Clin Cancer Res 2019; 25: 2185-2193.","DOI":"10.1158\/1078-0432.CCR-18-3042"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"103897","DOI":"10.1016\/j.ebiom.2022.103897","article-title":"Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer","volume":"77","author":"Zhang","year":"2022","unstructured":"Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Ge W, Li S, Yue M, Ma J, Yao J, Wang Y, Wang Y, Shentu D, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L and Wang L. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine 2022; 77: 103897.","journal-title":"EBioMedicine"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41575-020-0321-9","article-title":"The genomic landscape of recurrent pancreatic cancer is modified by treatment","volume":"17","author":"Xie","year":"2020","unstructured":"Xie IY and Gallinger S. The genomic landscape of recurrent pancreatic cancer is modified by treatment. Nat Rev Gastroenterol Hepatol 2020; 17: 389-390.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1200\/JCO.2022.40.16_suppl.4137","article-title":"Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network","volume":"40","author":"Poruk","year":"2022","unstructured":"Poruk KE, Moran A, Doctor V, Elvin JA, Radhi S, Loaiza-Bonilla A, Schink JC and Markman M. Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network. J Clin Oncol 2022; 40: 4137-4137.","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"8841","DOI":"10.3390\/ijms21228841","article-title":"Morphologic and molecular landscape of pancreatic cancer variants as the basis of new therapeutic strategies for precision oncology","volume":"21","author":"Bazzichetto","year":"2020","unstructured":"Bazzichetto C, Luchini C, Conciatori F, Vaccaro V, Di Cello I, Mattiolo P, Falcone I, Ferretti G, Scarpa A, Cognetti F and Milella M. Morphologic and molecular landscape of pancreatic cancer variants as the basis of new therapeutic strategies for precision oncology. Int J Mol Sci 2020; 21: 8841.","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.pan.2022.07.010","article-title":"The molecular landscape of pancreatic ductal adenocarcinoma","volume":"22","author":"Sivapalan","year":"2022","unstructured":"Sivapalan L, Kocher HM, Ross-Adams H and Chelala C. The molecular landscape of pancreatic ductal adenocarcinoma. Pancreatology 2022; 22: 925-936.","journal-title":"Pancreatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","article-title":"Immunotherapy and prevention of pancreatic cancer","volume":"4","author":"AH","year":"2018","unstructured":"Morrison AH, Byrne KT and Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 2018; 4: 418-428.","journal-title":"Trends Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.pan.2016.12.010","article-title":"Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters","volume":"17","author":"Dauer","year":"2017","unstructured":"Dauer P, Nomura A, Saluja A and Banerjee S. Microenvironment in determining chemo-resistance in pancreatic cancer: neighborhood matters. Pancreatology 2017; 17: 7-12.","journal-title":"Pancreatology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.3390\/cancers13164138","article-title":"Pancreatic cancer and immunotherapy: a clinical overview","volume":"13","author":"Timmer","year":"2021","unstructured":"Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, Wilmink JW, van der Vliet HJ, Meijerink MR, Scheffer HJ and de Gruijl TD. Pancreatic cancer and immunotherapy: a clinical overview. Cancers (Basel) 2021; 13: 4138.","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Laface C, Memeo R, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, Cazzato G, Guarini C, De Santis P, Perrone M and Fedele P. Immunotherapy and pancreatic cancer: a lost challenge? Life (Basel) 2023; 13: 1482.","DOI":"10.3390\/life13071482"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF and Linehan DC. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol 2022; 40: 2789-2805.","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","article-title":"Translational advances in pancreatic ductal adenocarcinoma therapy","volume":"3","author":"Hosein","year":"2022","unstructured":"Hosein AN, Dougan SK, Aguirre AJ and Maitra A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer 2022; 3: 272-286.","journal-title":"Nat Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.omto.2022.01.010","article-title":"The next wave of cellular immunotherapies in pancreatic cancer","volume":"24","author":"Yeo","year":"2022","unstructured":"Yeo D, Giardina C, Saxena P and Rasko JEJ. The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics 2022; 24: 561-576.","journal-title":"Mol Ther Oncolytics"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.20517\/cdr.2020.13","article-title":"The dark side of immunotherapy: pancreatic cancer","volume":"3","author":"Mucciolo","year":"2020","unstructured":"Mucciolo G, Roux C, Scagliotti A, Brugiapaglia S, Novelli F and Cappello P. The dark side of immunotherapy: pancreatic cancer. Cancer Drug Resist 2020; 3: 491-520.","journal-title":"Cancer Drug Resist"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"AS","year":"2020","unstructured":"Bear AS, Vonderheide RH and O&#x2019;Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 2020; 38: 788-802.","journal-title":"Cancer Cell"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-20-0775","article-title":"Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression","volume":"11","author":"Francescone","year":"2021","unstructured":"Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, Wagner J, Muir A, Lau AN, Gabitova L, Pazina T, Gupta S, Luong T, Rollins D, Malik R, Thapa RJ, Restifo D, Zhou Y, Cai KQ, Hensley HH, Tan Y, Kruger WD, Devarajan K, Balachandran S, Klein-Szanto AJ, Wang H, El-Deiry WS, Vander Heiden MG, Peri S, Campbell KS, Astsaturov I and Cukierman E. Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression. Cancer Discov 2021; 11: 446-479.","journal-title":"Cancer Discov"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","unstructured":"Carneiro BA and El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 2020; 17: 395-417.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41418-022-01059-z","article-title":"Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries","volume":"30","author":"Montinaro","year":"2023","unstructured":"Montinaro A and Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ 2023; 30: 237-249.","journal-title":"Cell Death Differ"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jconrel.2020.07.013","article-title":"TRAIL therapy and prospective developments for cancer treatment","volume":"326","author":"Thapa","year":"2020","unstructured":"Thapa B, Kc R and Uluda&#x11F; H. TRAIL therapy and prospective developments for cancer treatment. J Control Release 2020; 326: 335-349.","journal-title":"J Control Release"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"628332","DOI":"10.3389\/fmolb.2021.628332","article-title":"The TRAIL in the treatment of human cancer: an update on clinical trials","volume":"8","author":"Snajdauf","year":"2021","unstructured":"Snajdauf M, Havlova K, Vachtenheim J Jr, Ozaniak A, Lischke R, Bartunkova J, Smrz D and Strizova Z. The TRAIL in the treatment of human cancer: an update on clinical trials. Front Mol Biosci 2021; 8: 628332.","journal-title":"Front Mol Biosci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1359-6101(03)00029-7","article-title":"Apo2L\/TRAIL: apoptosis signaling, biology, and potential for cancer therapy","volume":"14","author":"Almasan","year":"2003","unstructured":"Almasan A and Ashkenazi A. Apo2L\/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-348.","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","article-title":"TRAIL on trial: preclinical advances in cancer therapy","volume":"19","author":"Stuckey","year":"2013","unstructured":"Stuckey DW and Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 2013; 19: 685-694.","journal-title":"Trends Mol Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","unstructured":"Lemke J, von Karstedt S, Zinngrebe J and Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21: 1350-1364.","journal-title":"Cell Death Differ"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2217\/fon-2020-0727","article-title":"Revisiting the role of TRAIL\/TRAIL-R in cancer biology and therapy","volume":"17","author":"Singh","year":"2021","unstructured":"Singh D, Tewari M, Singh S and Narayan G. Revisiting the role of TRAIL\/TRAIL-R in cancer biology and therapy. Future Oncol 2021; 17: 581-596.","journal-title":"Future Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI34359","article-title":"To kill a tumor cell: the potential of proapoptotic receptor agonists","volume":"118","author":"Ashkenazi","year":"2008","unstructured":"Ashkenazi A and Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118: 1979-1990.","journal-title":"J Clin Invest"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/83416","article-title":"Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells","volume":"7","author":"Takeda","year":"2001","unstructured":"Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H and Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94-100.","journal-title":"Nat Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/biom11040499","article-title":"Regulation of cancer metastasis by TRAIL\/death receptor signaling","volume":"11","author":"YT","year":"2021","unstructured":"Oh YT and Sun SY. Regulation of cancer metastasis by TRAIL\/death receptor signaling. Biomolecules 2021; 11: 499.","journal-title":"Biomolecules"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1002\/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B","article-title":"Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha\/beta","volume":"31","author":"Sato","year":"2001","unstructured":"Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, Yagita H, Okumura K, Tanaka N, Taniguchi T and Ogasawara K. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha\/beta. Eur J Immunol 2001; 31: 3138-3146.","journal-title":"Eur J Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/ng1097-141","article-title":"KILLER\/DR5 is a DNA damage-inducible p53-regulated death receptor gene","volume":"17","author":"GS","year":"1997","unstructured":"Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G and El-Deiry WS. KILLER\/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.","journal-title":"Nat Genet"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Wu GS, Kim K and El-Deiry WS. KILLER\/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol 2000; 465: 143-151.","DOI":"10.1007\/0-306-46817-4_13"},{"key":"ref37","unstructured":"Wu GS, Burns TF, Zhan Y, Alnemri ES and El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER\/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999; 59: 2770-2775."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.onc.1203489","article-title":"Wild-type p53 transactivates the KILLER\/DR5 gene through an intronic sequence-specific DNA-binding site","volume":"19","author":"Takimoto","year":"2000","unstructured":"Takimoto R and El-Deiry WS. Wild-type p53 transactivates the KILLER\/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735-1743.","journal-title":"Oncogene"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"15095","DOI":"10.1073\/pnas.2435285100","article-title":"Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy","volume":"100","author":"Wang","year":"2003","unstructured":"Wang S and El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 2003; 100: 15095-15100.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1158\/0008-5472.CAN-04-1734","article-title":"Inducible silencing of KILLER\/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil","volume":"64","author":"Wang","year":"2004","unstructured":"Wang S and El-Deiry WS. Inducible silencing of KILLER\/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004; 64: 6666-6672.","journal-title":"Cancer Res"},{"key":"ref41","unstructured":"Kim K, Fisher MJ, Xu SQ and El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335-346."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1128\/MCB.25.5.2000-2013.2005","article-title":"DR5 knockout mice are compromised in radiation-induced apoptosis","volume":"25","author":"Finnberg","year":"2005","unstructured":"Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T and El-Deiry WS. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 2005; 25: 2000-2013.","journal-title":"Mol Cell Biol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1172\/JCI29900","article-title":"TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis","volume":"118","author":"Finnberg","year":"2008","unstructured":"Finnberg N, Klein-Szanto AJ and El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008; 118: 111-123.","journal-title":"J Clin Invest"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.4161\/cbt.7.12.7460","article-title":"TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death","volume":"7","author":"Kuribayashi","year":"2008","unstructured":"Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS and El-Deiry WS. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008; 7: 2034-2038.","journal-title":"Cancer Biol Ther"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS and El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5: 171ra17.","DOI":"10.1126\/scitranslmed.3004828"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.18632\/oncotarget.27773","article-title":"TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic","volume":"11","author":"Ralff","year":"2020","unstructured":"Ralff MD, Jhaveri A, Ray JE, Zhou L, Lev A, Campbell KS, Dicker DT, Ross EA and El-Deiry WS. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget 2020; 11: 3753-3769.","journal-title":"Oncotarget"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/15384047.2021.1977067","article-title":"Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo","volume":"22","author":"Ray","year":"2021","unstructured":"Ray JE, Ralff MD, Jhaveri A, Zhou L, Dicker DT, Ross EA and El-Deiry WS. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo. Cancer Biol Ther 2021; 22: 554-563.","journal-title":"Cancer Biol Ther"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/15384047.2021.1976567","article-title":"Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo","volume":"22","author":"Jhaveri","year":"2021","unstructured":"Jhaveri AV, Zhou L, Ralff MD, Lee YS, Navaraj A, Carneiro BA, Safran H, Prabhu VV, Ross EA, Lee S and El-Deiry WS. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo. Cancer Biol Ther 2021; 22: 607-618.","journal-title":"Cancer Biol Ther"},{"key":"ref49","unstructured":"Parker CS, Zhou L, Prabhu VV, Lee S, Miner TJ, Ross EA and El-Deiry WS. ONC201\/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma. Am J Cancer Res 2023; 13: 6290-6312."},{"key":"ref50","unstructured":"Lulla AR, Zhou Y, Ralff MD, Lev A, Dicker DT and El-Deiry WS. miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells. Am J Cancer Res 2022; 12: 315-326."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/hep.28520","article-title":"Paving the TRAIL to anti-fibrotic therapy","volume":"64","author":"Guicciardi","year":"2016","unstructured":"Guicciardi ME and Gores GJ. Paving the TRAIL to anti-fibrotic therapy. Hepatology 2016; 64: 29-31.","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"682844","DOI":"10.3389\/fmats.2021.682844","article-title":"Long circulation of PEG-TRAIL improves anti-hepatic fibrosis effect of TRAIL via targeting activated hepatic stellate cells","volume":"8","author":"Lu","year":"2021","unstructured":"Lu B, Peng L, Luo S, Zhou J, Xu N, Dong C, Yan Z, Li H and Li Q. Long circulation of PEG-TRAIL improves anti-hepatic fibrosis effect of TRAIL via targeting activated hepatic stellate cells. Front Mater 2021; 8: 682844.","journal-title":"Front Mater"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"7934362","DOI":"10.1155\/2018\/7934362","article-title":"TRAIL-dependent resolution of pulmonary fibrosis","volume":"2018","author":"Habiel","year":"2018","unstructured":"Habiel DM, Moreira AP, Ismailoglu UB, Dunleavy MP, Cavassani KA, van Rooijen N, Coelho AL and Hogaboam CM. TRAIL-dependent resolution of pulmonary fibrosis. Mediators Inflamm 2018; 2018: 7934362.","journal-title":"Mediators Inflamm"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.28432","article-title":"Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells","volume":"64","author":"Oh","year":"2016","unstructured":"Oh Y, Park O, Swierczewska M, Hamilton JP, Park JS, Kim TH, Lim SM, Eom H, Jo DG, Lee CE, Kechrid R, Mastorakos P, Zhang C, Hahn SK, Jeon OC, Byun Y, Kim K, Hanes J, Lee KC, Pomper MG, Gao B and Lee S. Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Hepatology 2016; 64: 209-223.","journal-title":"Hepatology"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1535-7163.MCT-09-1076","article-title":"Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand","volume":"9","author":"Chae","year":"2010","unstructured":"Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S, Youn YS, Kim K, Jo DG, Kwon IC, Chen X and Lee KC. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther 2010; 9: 1719-1729.","journal-title":"Mol Cancer Ther"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Koizumi M, Hiasa Y, Kumagi T, Yamanishi H, Azemoto N, Kobata T, Matsuura B, Abe M and Onji M. Increased B cell-activating factor promotes tumor invasion and metastasis in human pancreatic cancer. PLoS One 2013; 8: e71367.","DOI":"10.1371\/journal.pone.0071367"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0160183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:42Z","timestamp":1766022642000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0160183.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/roat5658","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.29.610345","asserted-by":"object"}]},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}